Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 9/20 | 0.55 |
| ▸ | CYP11B2 | P19099 | 9/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.55 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.54 |
| ▸ | PIP4K2B | P78356 | 1/20 | 0.54 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.51 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.49 |
| ▸ | CDK1 | P06493 | 2/20 | 0.49 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.49 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.49 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.49 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.49 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.49 |
| ▸ | CCNT2 | O60583 | 1/20 | 0.49 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.49 |
| ▸ | CDK2 | P24941 | 1/20 | 0.49 |
| ▸ | CDK9 | P50750 | 1/20 | 0.49 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.49 |
| ▸ | TDP2 | O95551 | 2/20 | 0.49 |
| ▸ | JAK2 | O60674 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5830094 | 0.85 | PIP4K2A (0.56) | CYP11B1CYP11B2CYP1A2PIP4K2APIP4K2B | |
| SCHEMBL29899546 | 0.83 | PIP4K2A (0.51) | PIP4K2APIP4K2BCCNB2CDK1CCNB1 | |
| SCHEMBL152990 | 0.83 | PIP4K2A (0.51) | PIP4K2APIP4K2BCCNB2CDK1CCNB1 | |
| SCHEMBL5843496 | 0.81 | JAK2 (0.51) | PIP4K2APIP4K2BCCNB2CDK1CCNB1 | |
| SCHEMBL19145392 | 0.80 | ABL1 (0.54) | PIP4K2APIP4K2BCCNB2CDK1CCNB1 | |
| SCHEMBL3936784 | 0.79 | PIP4K2A (0.47) | CYP11B1CYP11B2CYP1A2PIP4K2APIP4K2B | |
| Acetic Acid SCHEMBL5831403 | 0.79 | PIP4K2A (0.48) | PIP4K2APIP4K2BCCNB2CDK1CCNB1 | |
| SCHEMBL5830722 | 0.79 | PIP4K2A (0.56) | PIP4K2APIP4K2BCCNB2CDK1CCNB1 | |
| SCHEMBL16090379 | 0.78 | BRD4 (0.52) | PIP4K2APIP4K2BCCNB2CDK1CCNB1 | |
| SCHEMBL7003835 | 0.77 | BRD4 (0.58) | PIP4K2APIP4K2BCCNB2CDK1CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7053086-B2 | 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors | SUGEN, INC. (US) | 2006-05-30 | — | — | US | disclosed |
| US-20040097497-A1 | 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors | SUGEN, INC. | 2004-05-20 | — | — | US | disclosed |
| US-6635640-B2 | 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors | SUGEN, INC. | 2003-10-21 | — | — | US | disclosed |
| US-20020187978-A1 | 4-Heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors | SUGEN, INC. | 2002-12-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020187978-A1 | 4-Heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors | CDK2, CDK20, CDK3 | CYP11B1 753/4885CYP11B2 892/4885CYP1A2 1079/4885 |
| US-20040097497-A1 | 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors | CDK2, CDK20, CDK3 | CYP11B1 753/4885CYP11B2 892/4885CYP1A2 1079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.